Ann: Percheron launches post-trial access program, page-56

You have no idea what your talking about. People like you and other's who are whining about management and the CR should put their money in the bank on term deposit. Let me point out some facts
* One of managements key responsibility's in running any company is having a strong balance sheet PARTICULARY LISTED COMPANY'S.
* It is critical for management to have a strong balance sheet when negotiating with potential partners to protect shareholder value, so we don't get screwed over during negotiations.
* There is one hundred percent chance that our partner will be a US based company. If you had not notice there has just been an election in the US in which are potential partners would have most likely wanted to see the outcome before investing.
* Our cash runway would have most likely expired in early 2025, partly because if you take the time to read the announcements from the company ATL1102 has been granted for continued use on compassionate grounds. Who do you think is going to pay for the manufacture admin and delivery to patience, it all costs and eats into our cash reserves.
* Institutions have invested heavily in this placement. The company does not need the SPP to shareholders, this has only been done through courtesy.
* There has already been a well written previous post in regards to continue use of a drug once a trial has finished and the criteria that must be meet. I suggest you read it.
* In regards to the 24cent CR if it was not for that CR at that time and at that price we would be in a power of trouble. It has funded the company to get us where we are now.
In summary I don't like CR and I don't like big bonus being paid to directors, but I accept that that is part of the course when investing in listed company's. This company is on the precipice of something amazing. (pending positive data) Now is not the time for bitching and moaning, now is the time to let the director's do what needs to be done.